leisure time -WSS

leisure time

author：explore 2025-10-04 10:24:32 - browse：74

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

WSS

General Catalyst, Summa Health deal will turn on physician buy

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Sen. Paul opposes bill to ban Chinese biotechs

Quicker fix for pulse oximeters urged during FDA public meeting

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Time to name cancers by genetics, not organ of origin, expert says

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Jerome Adams on the need for new antivirals for Covid

Covid misinformation case heads to Supreme Court

The cancer drug shortage isn’t new — and neither are the solutions

With psoriasis trial ahead, Alumis raises $259 million

Walensky prepares to leave CDC — and Congress — behind

The problem with charging patients to message their doctors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ARCH Venture Partners is raising $3 billion for a life sciences fund

Psychedelics group wrestles with new pharma identity

Some dementia cases could be undiagnosed liver disease

focus

The problem with charging patients to message their doctors

What we need to know about Arena Bioworks

Even great ERs can’t make up for American health disparities

Change Healthcare payments predicted restored March 15

SAMSHA loosens regulations on methadone treatment centers

Vertex non

Wikipedia

hotspot

focus

hotspot